<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52623">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02421120</url>
  </required_header>
  <id_info>
    <org_study_id>HHC-2015-0107</org_study_id>
    <nct_id>NCT02421120</nct_id>
  </id_info>
  <brief_title>Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients</brief_title>
  <official_title>A Prospective, Multicenter, Open-Label Study to Assess Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients Admitted With Acute Pulmonary Exacerbation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph Kuti</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cubist Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Christopher's Hospital for Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hartford Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is established evidence that adult patients with Cystic Fibrosis (CF) may have altered
      antibiotic pharmacokinetics compared with non-CF patients. Ceftolozane/Tazobactam is a newly
      approved broad spectrum intravenous antibiotic, which has potent in vitro activity against
      multidrug resistant Pseudomonas aeruginosa, the most common pathogen implicated in CF
      pulmonary exacerbations. This study will determine the pharmacokinetics and tolerability of
      ceftolozane/tazobactam in 20 adult CF patients admitted for a pulmonary exacerbation at one
      of 4 participating hospitals in the US. Patients will remain on standard of care IV
      antibiotics and receive 4-6 doses of ceftolozane/tazobactam 3 grams every 8 hours. Blood
      will be sampled after the final dose to determine concentrations and pharmacokinetics of
      ceftolozane and tazobactam. Safety and tolerability will be assessed throughout the 3 day
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will receive 4-6 doses of ceftolozane/tazobactam 3 grams every 8 hours, in
      addition to standard intravenous antibiotic therapy selected by the site. Just prior and
      then after the final dose, a total of six blood samples will be collected to measure
      ceftolozane and tazobactam concentrations. Data will be fit to a population pharmacokinetic
      model. The final model will be utilized in a Monte Carlo simulation to determine the
      probability of several different dosing regimens retaining concentrations above the minimum
      inhibitory concentration (MIC) for at least 39% of the dosing interval. These data will be
      utilized to determine an optimized dosing regimen for adults with CF.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ceftolozane Clearance</measure>
    <time_frame>8 hours</time_frame>
    <description>This outcome determines the clearance of ceftolozane over the 8 hour dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ceftolozane Volume of Distribution</measure>
    <time_frame>8 hours</time_frame>
    <description>This outcome determines the volume of distribution of ceftolozane over the 8 hour dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tazobactam Clearance</measure>
    <time_frame>8 hours</time_frame>
    <description>This outcome determines the clearance of tazobactam over the 8 hour dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tazobactam Volume of Distribution</measure>
    <time_frame>8 hours</time_frame>
    <description>This outcome determines the volume of distribution of tazobactam over the 8 hour dosing interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ceftolozane Probability of Target Attainment</measure>
    <time_frame>24 hours</time_frame>
    <description>This simulated outcome indicates the likelihood that ceftolozane will retain drug concentrations above the MIC for &gt;/= 39% of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability (changes in serum chemistry, hematology and hepatic lab values, as well as reported adverse events)</measure>
    <time_frame>3 days</time_frame>
    <description>This outcome will assess the safety and tolerability of ceftolozane/tazobactam in adults with CF after 4-6 doses, as measured by changes in serum chemistry, hematology and hepatic lab values, as well as reported adverse events by patients and providers.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Cystic Fibrosis Pulmonary Exacerbation</condition>
  <condition>Pseudomonas Aeruginosa Infection</condition>
  <arm_group>
    <arm_group_label>Ceftolozane/Tazobactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ceftolozane/Tazobactam 3 grams every 8 hours intravenously for 4-6 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftolozane/Tazobactam</intervention_name>
    <description>1 hour intravenous infusion</description>
    <arm_group_label>Ceftolozane/Tazobactam</arm_group_label>
    <other_name>Zerbaxa</other_name>
    <other_name>CXA-101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or older

          2. Documented diagnosis of CF

          3. Acute pulmonary exacerbation as the primary reason for admission to the hospital with
             requirement to receive systemic antibiotic treatment

          4. If female, subjects must be non-pregnant and non-lactating. Females can be either not
             of a child-bearing potential or if of a child-bearing potential, on acceptable modes
             of birth control such as abstinence from sexual intercourse, oral/parenteral
             contraceptives, or barrier method

        Exclusion Criteria:

          1. History of any moderate or severe hypersensitivity or allergic reaction to any
             Î²-lactam antibiotic (a history of mild rash to a cephalosporin followed by uneventful
             re-exposure is not a contraindication)

          2. Prior (within 24 hours of first dose of study drug) or concomitant receipt of
             piperacillin/tazobactam or probenecid

          3. History of lung transplant

          4. Moderate to severe renal dysfunction defined as a creatinine clearance &lt; 50 mL/min
             (as calculated by the Cockcroft-Gault equation using actual body weight) or
             requirement for continuous renal replacement therapy or hemodialysis

          5. A hemoglobin less than 8 gm/dl at baseline

          6. Any rapidly-progressing disease or immediately life-threatening illness (defined as
             imminent death within 48 hours in the opinion of the investigator)

          7. Any condition or circumstance that, in the opinion of the investigator, would
             compromise the safety of the patient or the quality of study data

          8. Planned or prior participation in any other interventional drug study within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph L Kuti, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hartford Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children at Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Medical Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 18, 2016</lastchanged_date>
  <firstreceived_date>April 13, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hartford Hospital</investigator_affiliation>
    <investigator_full_name>Joseph Kuti</investigator_full_name>
    <investigator_title>Associate Director, Clinical and Economic Studies</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
    <mesh_term>Ceftolozane, tazobactam drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
